Physician profile
John D Bedell
NPI 1528254570
$13,813.37
in general payments reported to CMS, 2019-2025
55 companies · $719 in 2025
The $719 reported for 2025 was more than what 80% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,612 · 2020: $2,574 · 2021: $3,195 · 2022: $1,775 · 2023: $905 · 2024: $2,034 · 2025: $719.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,658.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,658.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $1,494.01 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Novo Nordisk INC | $1,426.57 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $1,149.51 | 2019-2025 | Qulipta, Linzess, Viberzi |
| Amgen INC. | $997.43 | 2019-2025 | Repatha, Otezla, Repatha |
| Glaxosmithkline, LLC. | $844.34 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $820.81 | 2019-2024 | Jardiance, Synjardy, Tradjenta |
| Lilly USA, LLC | $741.16 | 2019-2024 | Jardiance, Mounjaro, Zepbound |
| Pfizer INC. | $682.91 | 2019-2024 | |
| Amarin Pharma, INC. | $602.10 | 2019-2022 | |
| Allergan, INC. | $514.11 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $488.75 | 2019-2022 | |
| Indivior INC. | $412.62 | 2019-2025 | Sublocade |
| Esperion Therapeutics, INC. | $410.82 | 2020-2024 | Nexletol |
| Novartis Pharmaceuticals Corporation | $300.41 | 2019-2025 | |
| Gilead Sciences, INC. | $268.36 | 2019-2023 |
Show all 55 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Bedell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.